Skip to main content
Two surgeons dressed in surgical gowns, masks, and head coverings are looking at a monitor during surgery
A skilled team, dedicated to you
We offer the best in neurosurgical care, from diagnosis to treatment and follow-up. Patients come from around the world to seek treatment from our internationally renowned experts, who are also strongly focused on robust research and clinical trials.  

About us

The Lenox Hill Brain Tumor Center offers comprehensive care for brain and spinal cord tumors in adults and children. Our experts utilize state-of-the-art surgical and nonsurgical techniques to treat tumors. In addition to our continuous pursuit of evidence-based medicine, the center emphasizes treatment of the whole patient and the crucial role of family in a patient's care.

Lenox Hill Neurosurgery is the only department in New York City to receive the 2018 Healthgrades Cranial Neurosurgery Excellence Award for superior outcomes in cranial neurosurgery. Additionally, Lenox Hill is one of only two hospitals in Manhattan to achieve an Excellent 30 day survival and Above Average patient safety score in the 2018 U.S. News & World Report rankings of the best hospitals for Neurology and Neurosurgery.

Brain Tumor Center at Lenox Hill Hospital

At Lenox Hill Neurosurgery, our team of neurosurgeons, nurse practitioners, and ENT specialists diagnose and treat complex brain tumors. Our world-renowned physicians are leaders in the treatment of these conditions and work diligently with researchers to develop new treatments.
 

Clinical expertise

Our center works closely with the Laboratory for Brain Tumor Biology and Therapy, and the Brain Tumor Biotech Center at the Feinstein Institute for Medical Research to offer cutting-edge diagnosis and treatment.

Our neurosurgeons utilize surgical and nonsurgical techniques to treat tumors and use state-of-the-art equipment such as image guided systems for precise surgical navigation and radiotherapy for painless, nonsurgical treatment.

Our multidisciplinary team specializes in treating all types of brain tumors, including:

Primary and metastatic brain tumors

  • Glioblastoma
  • Anaplastic astrocytoma
  • Gliomas
  • Ependymoma
  • Low-grade astrocytoma
  • Oligodendroglioma
  • Mixed oligoastrocytomas
  • Pilocytic astrocytoma
  • Medulloblastoma
  • Brainstem glioma
  • Meningiomas
  • Lymphoma
  • All brain metastasis including breast, lung, prostate, colon and melanoma metastasis 

Skull base tumors

  • Acoustic neuroma
  • Pituitary adenomas
  • Meningiomas
  • Chordomas
  • Chondrosarcomas
  • Glomus tumors
  • Craniopharyngioma
  • Metastatic tumors to the skull base
  • Squamous cell carcinoma of the head and neck
  • Esthesioneuroblastoma
  • Neuroendocrine carcinoma
  • Pineal region tumors including pinealblastoma and pinealcytoma
  • Lymphoma

Spinal cord tumors

  • Neurofibroma
  • Spinal metatastasis
  • Meningiomas
  • Chordomas
  • Chondrosarcomas
  • Schwannoma
  • Neurogangliomas
  • Metastatic tumors to the spinal cord
  • Myxopapillary ependymoma
Trusted excellence in neurosurgical care
Award-winning care, because you deserve the best

Lenox Hill is the only hospital in NYC to receive the 2018 Healthgrades Cranial Neurosurgery Excellence Award

Lenox Hill is the first hospital in the country to acquire a videomicroscope, a device that offers astounding magnified, high-resolution, 3D images—helping surgeons perform and collaborate on delicate brain and spine operations.

Two middle aged women talk to each other in a group setting
Brain cancer support group with yoga

Our patient and caregiver-focused group meets on the fourth Monday of each month from 5pm to 6:30pm. Sessions end with Yinyasa yoga; please bring a mat if you have one. Light refreshments will be served. RSVP to Sherese Fralin, NP, at [email protected] or (212) 434-4772. 
 

Research

The research arm of the Lenox Hill Brain Tumor Center is the Laboratory for Brain Tumor Biology and Therapy at the Feinstein Institute for Medical Research. The lab draws experts from multiple disciplines to participate in leading-edge research into brain and spinal cord tumors.

Our neuroscientists use discoveries in the lab to create new treatments for patients through a robust clinical trial program. Our doctors run the Brain Tumor Biotech Center at the Feinstein Institute, which is the only biotech center in the world dedicated to accelerating treatments for patients with brain tumors.

Clinical trials

Our patients have access to clinical studies offering novel, state-of-the-art therapies developed by our own physicians, as well as those that are done in collaboration with other sites. Ongoing trials include the following:

Phase 1 Trial of Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption for the Treatment of Cerebral Metastases of HER2/neu Positive Breast Cancer 
PI: John Boockvar, MD

The purpose of this study is to evaluate the safety of administering a single dose of trastuzumab into your artery for the treatment of your brain metastasis(es) from HER2/neu positive breast cancer. This study will try to determine the best tolerated single dosage of trastuzumab administered into arteries by gradually increasing the dosage given to participants as the study progresses. Early participants will receive a dosage of 1 mg/kg. As more participants enroll into the study, this single dosage will be increased at designated levels up to 8 mg/kg, if it’s determined to be safe to increase. Trastuzumab is a type of antibody, which is a protein used by the body’s immune system to fight against pathogens such as bacteria and viruses. This antibody binds to cell receptors known as the HER2/neu tyrosine kinase receptor. These receptors are expressed in certain cancer subtypes such as breast cancer. By blocking signaling through this HER2/neu receptor, trastuzumab can slow down or stop the over-expression of the HER2/neu protein. Over-expression of HER2/neu has been shown to play a role in the development and progression of certain types of breast cancer. Therefore, by slowing down or stopping the expression of HER2/neu, we hope to slow down or stop the growth of your metastasis(es) and increase the responsiveness to therapy.

Using genomic analysis to guide individualized treatment in glioblastoma multiforme (GBM). The purpose of this study is to assess whether the use of genomics can help identify patient specific treatment choices in cancer. In order to test this, we plan to use genomic sequencing technology to identify patient specific mutations in glioblastoma multiforme (GBM) as compared to normal cells of the blood from the same patient to identify mutations. Further analysis will identify potential treatment targets and whether there are any drugs that could be used for these particular mutations. Follow up clinical data will be assessed to see if this individualized method of choosing treatment options can improve clinical outcomes in patients with GBM.

Phase I Trial of Super-Selective Intra-Arterial Infusion of Cetuximab (ERBITUX) with or without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck 
PI: John Boockvar, MD

This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the head and neck (HNSCC). Cetuximab has recently emerged as a promising biological agent in the management of HNSCC. It is an epidermal growth factor receptor (EGFR) inhibitor which increases the radiosensitivity of tumors to radiotherapy (RT), and has been proven to be effective. A large body of evidence supports the theoretical attractiveness of intra-arterial chemotherapy, related to the first pass of the drug through the tumor bed and to the possibility of increasing the doses of the chemotherapeutic agent, thus minimizing systemic toxic side effects. Theoretically, a higher dose of Cetuximab saturating the tumor tissue’s EGFR receptor will increase its responsiveness with or without concurrent radiation therapy.

Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Temozolomide (Temodar) for Treatment of Newly Diagnosed Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD

This phase I clinical research trial will test the hypothesis that Temozolomide can be safely used by Superselective Intraarterial Cerebral Infusion (SIACI) up to a dose of 250mg/m2 to ultimately enhance survival of patients with newly diagnosed Glioblastoma Multiforme and Anaplastic Astrocytoma. Data suggests that Temozolomide is active in newly diagnosed GBM but that current response rates can be improved, and toxicity with systemic delivery could be avoided with selective delivery techniques such as SIACI.

Phase I/II Trial of Repeated Superselective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme
PI: John Boockvar, MD

This phase I/II clinical research trial will test the hypothesis that repeated dosing of of intra-arterial Bevacizumab at 15 mg/kg can be safely administered to enhance survival of subjects with newly diagnosed Glioblastoma multiforme while they receive standard of care. We expect that this project will provide important information regarding the utility of repeated SIACI Bevacizumab therapy for newly diagnosed malignant glioma, and may alter the way these drugs are delivered to our patients in the future.

Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma
PI: John Boockvar, MD

A recent study showed that IV Bevacizumab (Avastin) treatment was followed by clinically meaningful hearing improvement, tumor-volume reduction, or both, in some patients with vestibular schwannoma who were at risk for complete hearing loss or brainstem compression from growing VS. Because of these promising results in preliminary studies, and because of our significant experience with the safety of intraarterial chemotherapy, this novel study will offer a safe treatment for patients with VS. This is the only center in the United States where this trial is being offered.

Phase I Trial of Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD

Superselective Intraarterial Cerebral Infusion (SIACI) is a technique that can effectively increase the concentration of drug delivered to the brain while sparing the body of systemic side effects. One currently used drug called, Cetuximab (Erbitux) has been shown to be active in human brain tumors but its actual CNS penetration is unknown. This phase I clinical research trial will test the hypothesis that Cetuximab can be safely used by direct intraarterial infusion up to a dose of 250mg/m2 to ultimately enhance survival of patients with relapsed/refractory GBM/AA. This study will allow investigators to determine the the toxicity profile and maximum tolerated dose (MTD) of SIACI Cetuximab. The investigators expect that this study will provide important information regarding the utility of SIACI Cetuximab therapy for malignant gliomas, and may alter the way these drugs are delivered to the investigators patients in the near future.

Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD

This phase I/II clinical research trial will test the hypothesis that repeated direct intraarterial infusion Bevacizumab (15mg/kg) can be safely administered to enhance survival of patients with relapsed/refractory Glioblastoma Multiforme and Anaplastic Astrocytoma. The current standard of care for recurring GBM is for patients to receive Bevacizumab (Avastin) intravenously (IV) at 10mg/kg every two weeks until their tumor grows more than 25%. This study will help investigators determine if IV therapy with Bevacizumab should be combined with repeated selected intra-arterial Bevacizumab to improve progression free and overall survival.

Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) Plus Carboplatin (Paraplatin) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD

This phase I/II clinical research trial is an extension of our Phase I IA Avastin trial in that we seek to test the hypothesis that repeated dosing of intraarterial Bevacizumab is safe and effective in the treatment of recurrent malignant glioma. Additionally we will investigate whether the combination with Carboplatin will further improve the treatment response. We will also determine if IV therapy with Bevacizumab with IV Carboplatin should be combined with repeated selected intra-arterial Bevacizumab plus Carboplatin to improve progression free and overall survival.

Phase I/II Trial Of Repeated Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma
PI: John Boockvar, MD

This phase I/II clinical research trial will test the hypothesis that repeated dosing of intra-arterial Cetuximab is safe and effective in the treatment of recurrent malignant glioma. We will also determine if IV therapy with Cetuximab should be combined with repeated selected intra-arterial Cetuximab to improve progression free and overall survival.

Facilities dedicated to research and education

Our staff is dedicated to educating the next generation of medical professionals at our renowned medical school.
 

We’re empowering imagination and supporting pioneering discovery to transform our field and create a better tomorrow.

This is an interactive hub for scientists, clinicians and biotech companies in the neuro-oncology space to join forces and accelerate the delivery of novel drugs to patients living with brain tumors.
 

In the news
Preliminary research in mice suggests that the Zika virus might be turned from foe into friend -- enlisted to curb deadly glioblastoma brain tumors.
While many high school students relish the summer to relax, Olivia Frischman, 16 and a rising junior, from Westchester, NY, decided to spend a portion of her summer at Lenox Hill Hospital shadowing John Boockvar, MD, neurosurgeon, director of the hospital's Brain Tumor Center and professor at the F…

Our doctors

John Andrew Boockvar, MD

Vice Chair, Department of Neurosurgery , Lenox Hill Hospital

Director, Brain Tumor and Pituitary/ Neuroendocrine Center , Lenox Hill Hospital, Investigator, Laboratory for Brain Tumor Biology , Feinstein Institute for Medical Research, Professor, Neurosurgery and Otolaryngology/Head and Neck Surgery , Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

David Langer, MD

Chair, Department of Neurosurgery, Lenox Hill Hospital

Director, Moyamoya Center, Professor, Neurosurgery and Radiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Jason A. Ellis, MD

Neurosurgeon, Lenox Hill Hospital

Assistant Professor, Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Rafael Alexander Ortiz, MD

Chief, Neuro-Endovascular Surgery and Interventional Neuroradiology , Lenox Hill Hospital

Associate Professor, Neurosurgery, Neurology and Radiology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Aashish Raman Patel, DO

Specialties: Neurology, Critical Care Medicine

Heustein Lu Sy, MD

Specialties: Internal Medicine, Critical Care Medicine

David Barrett Weintraub, MD

Specialties: Neurological Surgery

Peter Costantino, MD

Senior Vice President and Executive Director, Head and Neck Services , Northwell Health

Chair, Otolaryngology

Richard Braunstein, MD

Executive Director, Manhattan Eye, Ear and Throat Hospital

Vice President, Ophthalmology Services, Northwell Health, Interim Chair, Ophthalmology, Long Island Jewish Medical Center and North Shore University Hospital, Professor, Ophthalmology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Alexis Matthew Demopoulos, MD

Specialties: Neurooncology, Neurology

Dennis Harry Kraus, MD

Specialties: Otolaryngology, Head / Neck Surgery

Jane Ari Lee, MD

Specialties: Diagnostic Radiology, Neuroradiology

Jed Michael Pollack, MD

Specialties: Radiation Oncology

Bidyut Kumar Pramanik, MD

Chief - Neuroradiology of Radiology, Lenox Hill Hospital

Specialties: Diagnostic Radiology, Neuroradiology

Samuel Joseph Wahl, MD

Chairman - Approved by the Jan 14 Med Board of Pathology, Lenox Hill Hospital

Chairman-Credentials Committee - Approved by the Dec 10, 2013 Med Board of Pathology, Lenox Hill Hospital

Specialties: Anatomic / Clinical Pathology, Cytopathology

Todd Arthur Anderson, MD

Specialties: Anatomic / Clinical Pathology

Anuj Goenka, MD

Specialties: Radiation Oncology

Dana Shani, MD

Specialties: Hematology, Medical Oncology, Internal Medicine

Christopher G. Filippi, MD

Specialties: Diagnostic Radiology

Jamie Roberts Mitchell, MD

Attending Neuro-ophthalmologist, Lenox Hill Hospital and Manhattan Eye, Ear and Throat Hospital

Sewit Teckie, MD

Specialties: Radiation Oncology

Rosamaria Ruggieri, PhD

Assistant Investigator, Feinstein Institute for Medical Research

Assistant Professor, Department of Molecular Medicine and Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Marc Symons, PhD

Investigator, Feinstein Institute for Medical Research

Co-Director, Brain Tumor Biotech Center, Feinstein Institute for Medical Research, Professor, Department of Molecular Medicine and Department of Neurosurgery, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Clinical professionals

head shot of  Sherese Fralin

Sherese Fralin, MSN, FNP

Research Nurse Practictioner, Department of Neurosurgery, Lenox Hill Hospital

head shot of Tamika Wong

Tamika Wong, MPH

Clinical Research Manager, Department of Neurosurgery, Lenox Hill Hospital

head shot of Anupama Bedi

Anupama Bedi, MS, PA-C

Supervising Physician Assistant, Department of Neurosurgery, Lenox Hill Hospital

head shot of Andrea S. Adams

Andrea S. Adams, MS, RN, ANP-BC, SCRN

Adult Nurse Practitioner, Department of Neurosurgery, Lenox Hill Hospital

Go to top